SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-485709"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-485709" > Adjuvant capecitabi...

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients

de Boo, Leonora W. (författare)
Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
Jozwiak, Katarzyna (författare)
Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany.;Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands
Joensuu, Heikki (författare)
Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland
visa fler...
Lindman, Henrik (författare)
Uppsala universitet,Experimentell och klinisk onkologi
Lauttia, Susanna (författare)
Univ Helsinki, Lab Mol Oncol, Biomed Helsinki, Helsinki, Finland
Opdam, Mark (författare)
Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
van Steenis, Charlaine (författare)
Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
Brugman, Wim (författare)
Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
Kluin, Roelof J. C. (författare)
Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
Schouten, Philip C. (författare)
Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
Kok, Marleen (författare)
Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.;Netherlands Canc Inst, Div Tumor Biol & Immunol, Amsterdam, Netherlands
Nederlof, Petra M. (författare)
Antoni van Leeuwenhoek Hosp, Dept Pathol, Netherlands Canc Inst, Amsterdam, Netherlands
Hauptmann, Michael (författare)
Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany.;Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands
Linn, Sabine C. (författare)
Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands.;Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.;Univ Med Ctr, Dept Pathol, Utrecht, Netherlands
visa färre...
Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany;Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands (creator_code:org_t)
2022-02-05
2022
Engelska.
Ingår i: British Journal of Cancer. - : Springer Nature. - 0007-0920 .- 1532-1827. ; 126:10, s. 1401-1409
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background The addition of adjuvant capecitabine to standard chemotherapy of early-stage triple-negative breast cancer (TNBC) patients has improved survival in a few randomised trials and in meta-analyses. However, many patients did not benefit. We evaluated the BRCA1-like DNA copy number signature, indicative of homologous recombination deficiency, as a predictive biomarker for capecitabine benefit in the TNBC subgroup of the FinXX trial.Methods Early-stage TNBC patients were randomised between adjuvant capecitabine-containing (TX + CEX: capecitabine-docetaxel, followed by cyclophosphamide-epirubicin-capecitabine) and conventional chemotherapy (T + CEF: docetaxel, followed by cyclophosphamide-epirubicin-fluorouracil). Tumour BRCA1-like status was determined on low-coverage, whole genome next-generation sequencing data using an established DNA comparative genomic hybridisation algorithm.Results For 129/202 (63.9%) patients the BRCA1-like status could be determined, mostly due to lack of tissue. During a median follow-up of 10.7 years, 35 recurrences and 32 deaths occurred. Addition of capecitabine appears to improve recurrence-free survival more among 61 (47.3%) patients with non-BRCA1-like tumours (HR 0.23, 95% CI 0.08-0.70) compared to 68 (52.7%) patients with BRCA1-like tumours (HR 0.66, 95% CI 0.24-1.81) (P-interaction = 0.17).Conclusion Based on our data, patients with non-BRCA1-like TNBC appear to benefit from the addition of capecitabine to adjuvant chemotherapy. Patients with BRCA1-like TNBC may also benefit. Additional research is needed to define the subgroup within BRCA1-like TNBC patients who may not benefit from adjuvant capecitabine.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy